Long-term cardiac follow-up in survivors of a malignant bone tumour

Ann Oncol. 2006 Oct;17(10):1586-91. doi: 10.1093/annonc/mdl156. Epub 2006 Jul 20.

Abstract

Background: Longitudinal studies of cardiac function in long-term childhood cancer survivors are scarce and frequently concern a median follow-up shorter than 13 years.

Patients and methods: Cardiac assessment was performed in 22 doxorubicin-treated long-term survivors of a malignant bone tumour at median 22 years (range 15-27.5) post-treatment. Age at follow-up was 39 years (range 27-59) and cumulative dose of doxorubicin was 360 mg/m(2) (range 225-550). Cardiac function was assessed by echocardiography and (24-h) ECG. The results were compared with those of earlier assessments at 9 years (1992) and 14 years (1997) post-treatment.

Results: Systolic dysfunction was found in 27% (9% in 1997; P = 0.02) and diastolic dysfunction in 45% (18% in 1997; P = 0.02). Heart rate variability showed further deterioration compared with earlier results.

Conclusions: Twenty-two years after doxorubicin-treatment, bone tumour survivors showed progressive cardiac dysfunction.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Blood Pressure / physiology
  • Bone Neoplasms / complications
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / physiopathology*
  • Child
  • Doxorubicin / adverse effects
  • Doxorubicin / therapeutic use
  • Echocardiography
  • Electrocardiography
  • Female
  • Heart Diseases / chemically induced*
  • Heart Diseases / etiology
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Osteosarcoma / complications
  • Osteosarcoma / drug therapy
  • Osteosarcoma / physiopathology*
  • Survivors*
  • Time

Substances

  • Antineoplastic Agents
  • Doxorubicin